1Abascal, K & Yarnell, E (2005) Using bitter melon to treat diabetes. Altern Complement Med 1, 179–184.
2Yadav, UC, Moorthy, K & Baquer, NZ (2005) Combined treatment of sodium orthovanadate and Momordica charantia fruit extract prevents alterations in lipid profile and lipogenic enzymes in alloxan diabetic rats. Mol Cell Biochem 268, 111–120.
3Chan, LL, Chen, Q, Go, AG, Lam, EK & Li, ET (2005) Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr 135, 2517–2523.
4Senanayake, GV, Maruyama, M, Shibuya, K, Sakono, M, Fukuda, N, Morishita, T, Yukizaki, C, Kawano, M & Ohta, H (2004) The effects of bitter melon (Momordica charantia) on serum and liver triglyceride levels in rats. J Ethnopharmacol 91, 257–262.
5Senanayake, GV, Maruyama, M, Sakono, M, Fukuda, N, Morishita, T, Yukizaki, C, Kawano, M & Ohta, H (2004) The effects of bitter melon (Momordica charantia) extracts on serum and liver lipid parameters in hamsters fed cholesterol-free and cholesterol-enriched diets. J Nutr Sci Vitaminol (Tokyo) 50, 253–257.
6Chaturvedi, P, George, S, Milinganyo, M & Tripathi, YB (2004) Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats. Phytother Res 18, 954–956.
7Chen, Q, Chan, LL & Li, ET (2003) Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr 133, 1088–1093.
8Virdi, J, Sivakami, S, Shahani, S, Suthar, AC, Banavalikar, MM & Biyani, MK (2003) Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol 88, 107–111.
9Bonn, V, Cheung, RC, Chen, B, Taghibiglou, C, Van Iderstine, SC & Adeli, K (2002) Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis 163, 59–68.
10Carpentier, A, Taghibiglou, C, Leung, N, Szeto, L, Van Iderstine, SC, Uffelman, KD, Buckingham, R, Adeli, K & Lewis, GF (2002) Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 277, 28795–28802.
11Sparks, JD, Phung, TL, Bolognino, M & Sparks, CE (1996) Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem J 313, 567–574.
12Avramoglu, RK & Adeli, K (2004) Hepatic regulation of apolipoprotein B. Rev Endocr Metab Disord 5, 293–301.
13Chong, T, Naples, M, Federico, L, Taylor, D, Smith, GJ, Cheung, RC & Adeli, K (2006) Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia. Atherosclerosis 185, 21–31.
14Taghibiglou, C, Rashid-Kolvear, F, Van Iderstine, SC, Le-Tien, H, Fantus, IG, Lewis, GF & Adeli, K (2002) Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and over expression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 277, 793–803.
15Nerurkar, PV, Pearson, L, Efird, JT, Adeli, K, Theriault, AG & Nerurkar, VR (2005) Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J Nutr 135, 702–706.
16Raj, SK, Khan, MS, Singh, R, Kumari, N & Prakash, D (2005) Occurrence of yellow mosaic geminiviral disease on bitter gourd (Momordica charantia) and its impact on phytochemical contents. Int J Food Sci Nutr 56, 185–192.
17Saha, PK, Kojima, H, Martinez-Botas, J, Sunehag, AL & Chan, L (2004) Metabolic adaptations in the absence of perilipin: increased beta-oxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in perilipin-null mice. J Biol Chem 279, 35150–35158.
18Scribner, K, Gadbois, T, Gowri, M, Azhar, S & Reaven, G (2000) Masoprocol decreases serum triglyceride concentrations in rats with fructose-induced hypertriglyceridemia. Metabolism 49, 1106–1110.
19Hui, DY (2003) HIV protease inhibitors and atherosclerosis. J Clin Invest 111, 317–318.
20Messier, C, Whately, K, Liang, J, Du, L & Puissant, D (2007) The effects of a high-fat, high-fructose, and combination diet on learning, weight, and glucose regulation in C57BL/6 mice. Behav Brain Res 178, 139–145.
21Avramoglu, RK, Basciano, H & Adeli, K (2006) Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 368, 1–19.
22Chen, Q & Li, ET (2005) Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. Br J Nutr 93, 747–754.
23Nerurkar, PV, Lee, YK, Linden, EH, Lim, S, Pearson, L, Frank, J & Nerurkar, VR (2006) Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2. Br J Pharmacol 148, 1156–1164.
24Shepherd, PR, Withers, DJ & Siddle, K (1998) Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling. Biochem J 333, 471–490.
25Arimura, N, Horiba, T, Imagawa, M, Shimizu, M & Sato, R (2004) The peroxisome proliferator-activated receptor gamma regulates expression of the perilipin gene in adipocytes. J Biol Chem 279, 10070–10076.
26Ueki, K, Fruman, DA, Yballe, CM, Fasshauer, M, Klein, J, Asano, T, Cantley, LC & Kahn, CR (2003) Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem 278, 48453–48466.
27Patsouris, D, Reddy, JK, Muller, M & Kersten, S (2006) Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147, 1508–1516.
28Ameen, C, Edvardsson, U, Ljungberg, A, Asp, L, Akerblad, P, Tuneld, A, Olofsson, SO, Linden, D & Oscarsson, J (2005) Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem 280, 1224–1229.
29Chao, CY & Huang, CJ (2003) Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and up regulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J Biomed Sci 10, 782–791.
30Jayasooriya, AP, Sakono, M, Yukizaki, C, Kawano, M, Yamamoto, K & Fukuda, N (2000) Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J Ethnopharmacol 72, 331–336.
31Ahmed, I, Lakhani, MS, Gillett, M, John, A & Raza, H (2001) Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 51, 155–161.
32Abd El Sattar El Batran, S, El-Gengaihi, SE & El Shabrawy, OA (2006) Some toxicological studies of Momordica charantia L. on albino rats in normal and alloxan diabetic rats. J Ethnopharmacol 108, 236–242.
33Khanna, P, Jain, SC, Panagariya, A & Dixit, VP (1981) Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 44, 648–655.
34Jantan, I, Rafi, IA & Jalil, J (2005) Platelet-activating factor (PAF) receptor-binding antagonist activity of Malaysian medicinal plants. Phytomedicine 12, 88–92.
35Anila, L & Vijayalakshmi, NR (2000) Beneficial effects of flavonoids from Sesamum indicum, Emblica officinalis and Momordica charantia. Phytother Res 14, 592–595.
36Harinantenaina, L, Tanaka, M, Takaoka, S, Oda, M, Mogami, O, Uchida, M & Asakawa, Y (2006) Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull (Tokyo) 54, 1017–1021.
37Welihinda, J, Karunanayake, EH, Sheriff, MH & Jayasinghe, KS (1986) Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 17, 277–282.
38Leatherdale, BA, Panesar, RK, Singh, G, Atkins, TW, Bailey, CJ & Bignell, AH (1981) Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed) 282, 1823–1824.
39Srivastava, Y, Venkatakrishna-Bhatt, H, Verma, Y, et al. (1993) Antidiabetic and adaptogenic properties of Momordica charantia extract. An experimental and clinical evaluation. Phytother Res 7, 285–289.
40Basch, E, Gabardi, S & Ulbricht, C (2003) Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 60, 356–359.
41Tuekpe, MK, Todoriki, H, Sasaki, S, Zheng, KC & Ariizumi, M (2006) Potassium excretion in healthy Japanese women was increased by a dietary intervention utilizing home-parcel delivery of Okinawan vegetables. Hypertens Res 29, 389–396.
42Ahmed, N, Hassan, MR, Halder, H & Bennoor, KS (1999) Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull 25, 11–13.